HC Wainwright & Co. Assumes OnKure Therapeutics at Buy, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on OnKure Therapeutics with a Buy rating and set a price target of $40.
October 17, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has assumed coverage of OnKure Therapeutics with a Buy rating and a price target of $40, indicating a positive outlook.
The Buy rating and $40 price target from a reputable firm like HC Wainwright & Co. suggests confidence in OnKure's future performance, likely leading to positive investor sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100